Increased safety level of serotype 3 sabin oral poliomyelitis vaccine lots by improved seed virus, and tissue culture and virus infection conditions

By Dorsam V.   Weimer T.   Schmeel A.   Hein B.   Enssle K.   Chumakov K.M.   Fibi M.R.  

Vaccine, Vol. 18, Iss. 22, 2000-05 ,pp. : 2435-2443

Elsevier

Access to resources Recommend Favorite

Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis

By Swartz T.A.   Handsher R.   Manor Y.   Stoeckel P.   Barkay A.   Mendelson E.   Leventhal A.  

Vaccine, Vol. 16, Iss. 20, 1998-12 ,pp. : 2090-2095

Elsevier

Access to resources Recommend Favorite

The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine

By Horie H.   Sato M.   Doi Y.   Hashizume S.  

Vaccine, Vol. 14, Iss. 1, 1996-01 ,pp. : 35-41

Elsevier

Access to resources Recommend Favorite

Poliomyelitis or acute flaccid paralysis in future

By Arya S.C.  

Vaccine, Vol. 18, Iss. 25, 2000-06 ,pp. : 2773-2774

Elsevier

Access to resources Recommend Favorite

Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B

By Kanra G.   Silier T.   Yurdakok K.   Yavuz T.   Baskan S.   Ulukol B.   Ceyhan M.   Ozmert E.   Turkay F.   Pehlivan T.  

Vaccine, Vol. 18, Iss. 9, 1999-12 ,pp. : 947-954

Elsevier

Access to resources Recommend Favorite